(AONC) American Oncology Network - Ratings and Ratios

American Oncology Network, Inc. (NASDAQ:AONC) operates as a provider of oncology services in the United States, delivering comprehensive care solutions through its subsidiaries. The company offers a range of specialized services, including laboratory testing for both routine and complex diagnostics, in-house pathology services with precise and timely reporting, and specialty pharmacy services that include patient education, financial support, and round-the-clock assistance. Additionally, AONC provides care management programs that encompass nutrition guidance and other supportive care elements. Headquartered in Fort Myers, Florida, the company was established in 2017 and has since expanded its network to enhance access to oncology care across the U.S.

From a technical perspective, AONCs stock has shown a declining trend, with its 20-day moving average at 5.05 and a 50-day moving average at 5.12, both above the current price of 4.80. The 200-day moving average of 3.55 indicates longer-term upward momentum, though recent price action suggests short-term weakness. The average true range (ATR) of 0.31 reflects moderate volatility. Fundamentally, the companys market cap stands at $130.01 million, with a price-to-sales (P/S) ratio of 0.08, indicating a relatively low valuation compared to its revenue. The return on equity (RoE) of 29.02% highlights strong profitability. However, the lack of forward P/E and a zero P/B ratio suggests uncertainty in earnings expectations. Over the next three months, AONCs stock is likely to remain range-bound between 4.20 and 5.50, with potential upside driven by improved earnings visibility and downside risks tied to broader market conditions.